Sodium-glucose co-transporter-2 (SGLT2, also called solute carrier family 5 [sodium/glucose cotransporter], member 2, SLC5A2) inhibitors are established as effective treatments for T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.